Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Jul 24:5:11743.
doi: 10.1038/srep11743.

Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic Stroke

Hai-rong Wang  1 , Miao Chen  1 , Fei-long Wang  1 , Li-hua Dai  1 , Ai-hua Fei  1 , Jia-fu Liu  1 , Hao-jun Li  1 , Sa Shen  1 , Ming Liu  1 , Shu-ming Pan  1
Affiliations
Clinical Trial

Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic Stroke

Hai-rong Wang et al. Sci Rep. .

Abstract

We aimed to compare the therapeutic effect of recombinant tissue plasminogen activator (rt-PA) administered at different time windows within the first 6 hours after onset of acute ischemic stroke (AIS). A retrospective analysis was performed of data collected from 194 patients who received rt-PA thrombolysis within 4.5 hours after AIS onset and from 29 patients who received rt-PA thrombolysis between 4.5-6 hours after AIS onset. The National Institutes of Health Stroke Scale (NIHSS) scores were statistically decreased in both groups (P < 0.05) at 24 hours and 7 days after onset. There was no statistical difference in the modified Rankin score or mortality at day 90 after treatment between the two groups (P > 0.05). In conclusion, AIS patients who received rt-PA treatment between 4.5-6 hours after onset were similar in therapeutic efficacy to those who received rt-PA within 4.5 hours after onset. Our results suggest that intravenous thrombolytic therapy for AIS within 4.5-6 hours after onset is effective and safe.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Comparison between NIHSS scores of the two groups before and after thrombolysis:
*indicates P < 0.05.
Figure 2
Figure 2. Comparison of improvement of NIHSS scores of patients after thrombolysis in the two groups:
△ P > 0.05.
Figure 3
Figure 3. Modified Rankin Scale scores of patients in the two groups 90 days after thrombolysis:
△ indicates P > 0.05.
See this image and copyright information in PMC

References

    1. Gao X. et al. Admission clinical characteristics and early clinical outcomes among acute ischemic stroke patients. J Biomed Res 26, 152–158 (2012). - PMC - PubMed
    1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333, 1581–1587 (1995). - PubMed
    1. Barber P. A., Zhang J., Demchuk A. M., Hill M. D. & Buchan A. M. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 56, 1015–1020 (2001). - PubMed
    1. Hacke W. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 274, 1017–1025 (1995). - PubMed
    1. Hacke W. et al. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352, 1245–1251 (1998). - PubMed

Substances